People with schizophrenia treated with second-generation antipsychotics (SGAs) have lower plasma adiponectin levels, as compared with general population, that may lead to metabolic abnormalities. However, the contribution of different SGAs on adiponectin dysregulation is still unclear. The objective of this systematic review and meta-analysis was to estimate differences in adiponectin levels among people with schizophrenia treated with different SGAs. We systematically searched for observational studies published up to March 2015 in main electronic databases. Different SGAs were included if data on adiponectin were available from at least three different samples involving as a minimum five participants per treatment arm. Standardized mean differences with relevant 95% confidence intervals were generated. I2 was used to test heterogeneity among studies. Eight studies were included with data suitable for carrying out four different comparisons: Clozapine vs. Olanzapine (including n=877 individuals with schizophrenia); Clozapine vs. Risperidone (n=660); Olanzapine vs. Risperidone (n=738); Quetiapine vs. Risperidone (n=186). There were no differences on adiponectin levels between people taking Clozapine and those taking Olanzapine (p=0.86), but high heterogeneity was detected (I2=82%). Both individuals taking Clozapine (p<0.001; I2=0%) and those taking Olanzapine (p=0.02; I2=9%), but not subjects treated with Quetiapine (p=0.47; I2=0%), had adiponectin levels significantly lower than people taking Risperidone. Our findings are consistent with previous evidence showing greater metabolic abnormalities attributable to Clozapine and Olanzapine, as compared with other SGAs. Although mechanisms whereby both these SGAs influence adiponectin remain unexplained, its reduction might mediate relevant abnormalities. Prospective evaluations of long-term effects of different SGAs on adiponectin are needed.

Bartoli, F., Crocamo, C., Clerici, M., Carra', G. (2015). Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 25(10), 1767-1774 [10.1016/j.euroneuro.2015.06.011].

Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis

BARTOLI, FRANCESCO
Primo
;
CROCAMO, CRISTINA;CLERICI, MASSIMO
Penultimo
;
CARRA', GIUSEPPE
Ultimo
2015

Abstract

People with schizophrenia treated with second-generation antipsychotics (SGAs) have lower plasma adiponectin levels, as compared with general population, that may lead to metabolic abnormalities. However, the contribution of different SGAs on adiponectin dysregulation is still unclear. The objective of this systematic review and meta-analysis was to estimate differences in adiponectin levels among people with schizophrenia treated with different SGAs. We systematically searched for observational studies published up to March 2015 in main electronic databases. Different SGAs were included if data on adiponectin were available from at least three different samples involving as a minimum five participants per treatment arm. Standardized mean differences with relevant 95% confidence intervals were generated. I2 was used to test heterogeneity among studies. Eight studies were included with data suitable for carrying out four different comparisons: Clozapine vs. Olanzapine (including n=877 individuals with schizophrenia); Clozapine vs. Risperidone (n=660); Olanzapine vs. Risperidone (n=738); Quetiapine vs. Risperidone (n=186). There were no differences on adiponectin levels between people taking Clozapine and those taking Olanzapine (p=0.86), but high heterogeneity was detected (I2=82%). Both individuals taking Clozapine (p<0.001; I2=0%) and those taking Olanzapine (p=0.02; I2=9%), but not subjects treated with Quetiapine (p=0.47; I2=0%), had adiponectin levels significantly lower than people taking Risperidone. Our findings are consistent with previous evidence showing greater metabolic abnormalities attributable to Clozapine and Olanzapine, as compared with other SGAs. Although mechanisms whereby both these SGAs influence adiponectin remain unexplained, its reduction might mediate relevant abnormalities. Prospective evaluations of long-term effects of different SGAs on adiponectin are needed.
Articolo in rivista - Articolo scientifico
Adiponectin; Meta-analysis; Schizophrenia; Second-generation antipsychotics
English
1767
1774
8
Bartoli, F., Crocamo, C., Clerici, M., Carra', G. (2015). Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 25(10), 1767-1774 [10.1016/j.euroneuro.2015.06.011].
File in questo prodotto:
File Dimensione Formato  
second generat.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 719.18 kB
Formato Adobe PDF
719.18 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/85476
Citazioni
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 42
Social impact